IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction

IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction

Background: Elevated interleukin-6 (IL-6) and complement activation are associated with detrimental effects of inflammation in coronary artery disease (CAD). The complement anaphylatoxins C5a and C3a interact with their receptors; the highly inflammatory C5aR1, and the C5aR2 and C3aR. We evaluated t...

Full description

Bibliographic Details
Main Authors: Hilde L. Orrem, Per H. Nilsson, Søren E. Pischke, Ola Kleveland, Arne Yndestad, Karin Ekholt, Jan K. Damås, Terje Espevik, Bjørn Bendz, Bente Halvorsen, Ida Gregersen, Rune Wiseth, Geir Ø. Andersen, Thor Ueland, Lars Gullestad, Pål Aukrust, Andreas Barratt-Due, Tom E. Mollnes
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Immunology
Subjects:
complement
C5a receptors
C3a receptor
IL-6
myocardial infarction
inflammation
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02035/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.02035/full

Similar Items